Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Front-line Ruxolitinib for Hyperinflammatory Stage II/III COVID-19
2020-001481-11Phase 2Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ruxolitinib in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Friedrich Schiller University Jena. Primary endpoint: Reduction in hyperinflammation score. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001481-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001481-11.